|1.||Karumanchi, S Ananth: 41 articles (11/2015 - 03/2003)|
|2.||Shibuya, Masabumi: 17 articles (01/2015 - 10/2002)|
|3.||Romero, Roberto: 15 articles (01/2015 - 06/2004)|
|4.||Rana, Sarosh: 12 articles (11/2015 - 02/2007)|
|5.||Chaiworapongsa, Tinnakorn: 12 articles (01/2015 - 06/2004)|
|6.||Wu, Yan: 12 articles (02/2011 - 11/2004)|
|7.||Thadhani, Ravi: 11 articles (11/2015 - 02/2004)|
|8.||Levine, Richard J: 11 articles (04/2009 - 02/2004)|
|9.||Kusanovic, Juan Pedro: 10 articles (04/2013 - 10/2006)|
|10.||Rajakumar, Augustine: 9 articles (10/2014 - 12/2004)|
09/01/2004 - "The retroviral gene transfer of the full length VEGFR-1 also caused a significant reduction of tumor growth in both models. "
07/12/2011 - "We found that efficacy of anti-PlGF treatment strongly correlates with VEGFR-1 expression in tumor cells, but not with antiangiogenesis. "
01/01/2013 - "Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor."
03/01/2010 - "In this study, we demonstrate that tumor-derived PlGF activates NFAT1 via vascular endothelial growth factor receptor 1 in both murine and human myelomonocytic cells. "
08/15/2008 - "This study shows that VEGFR-1 contributes to anti-EGFR drug resistance in different human cancer cells. "
|2.||Breast Neoplasms (Breast Cancer)
01/01/2013 - "Thus, the present study examined whether VEGFR-1 activation is associated with the invasiveness of breast cancer. "
01/01/2013 - "While VEGFR-1 expression is associated with poor prognosis of women with breast cancer, it is not clear whether it is involved in the aggressiveness of breast cancer. "
01/01/2013 - "Vascular endothelial growth factor receptor-1 activation promotes migration and invasion of breast cancer cells through epithelial-mesenchymal transition."
09/01/2012 - "High-level cytoplasmic expression of VEGFR-1 was associated with significantly reduced distant disease-free survival (DDFS) (P = 0.017, log-rank) and breast cancer-specific survival (BCSS) (P = 0.005, log-rank) for all patients, and for node-negative patients without systemic treatment (DDFS, P = 0.03, log-rank; BCSS, P = 0.009, log-rank). "
04/01/2011 - "Five hundred and seventy-nine non-metastatic lymph nodes from 49 patients affected by invasive breast cancer were submitted to an immunohistochemical comparative analysis of hematopoietic (CD34), endothelial (CD133), mesenchymal (CD117) progenitors and vascular endothelial growth factor receptor 1 (VEGFR1, also known as Flt1). "
|3.||Neoplasm Metastasis (Metastasis)
12/01/2014 - "Vascular endothelial growth factor receptor-1(+) hematopoietic progenitor cells (HPCs) have been shown to play an important role in metastasis, forming a 'pre-metastatic niche' at designated sites for distant tumour progression. "
11/01/2010 - "Collectively, our results indicate that liver metastases are more reliant on VEGFR-1 than lung metastases to mediate angiogenesis due to differential activity of VEGFRs on liver EC versus lung EC. "
01/01/2009 - "Furthermore, VEGFR-1 was found to promote metastasis through initiating pre-metastatic niche by VEGFR-1 positive bone marrow progenitors. "
05/01/2008 - "In the 380 patients who were ITC negative and showed low VEGFR-1 expression, synchronous (at the time of surgery) and heterochronous (recurrent) metastases were not observed. "
09/01/2007 - "However lack of expression of VEGFR-1 was significantly associated with lymphogenous and haematogenous metastases. "
07/01/2003 - "Thus, these preclinical studies show proof-of-principle that PlGF and VEGFR-1 are promising therapeutic targets to treat angiogenesis and inflammation related disorders. "
06/01/2012 - "Placental growth factor (PlGF) and its receptor vascular endothelial growth factor receptor 1 (VEGFR1) play an important role in pathological conditions related to angiogenesis, vascular leakage, and inflammation. "
10/01/2010 - "Notch1 deficiency results in decreased inflammation during wound healing and regulates vascular endothelial growth factor receptor-1 and inflammatory cytokine expression in macrophages."
01/01/2009 - "It was reported that VEGFR-1 had an active role in promoting inflammation through modulating immune cells and mediating immunosuppression by VEGFR-1 positive myeloid cells. "
09/15/2006 - "These results indicate that the VEGFR-1 TK signaling modulates the proliferation of bone marrow hematopoietic cells and immunity of monocytes/macrophages and promotes chronic inflammation, which may be a new target in the treatment of RA."
|5.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/01/2015 - "Mutations of Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD), accounting for approximately 30% of patients with acute myeloid leukemia (AML), results in poor therapeutic efficacy and short survival. "
10/10/2013 - "Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status."
11/17/2015 - "Internal tandem duplications within the juxtamembrane region of the FMS-like tyrosine kinase receptor FLT3 (FLT3-ITD) represents one of the most common mutations in patients with acute myeloid leukemia (AML) which results in constitutive aberrant activation, increased proliferation of leukemic progenitors and is associated with an aggressive clinical phenotype. "
04/10/2015 - "Internal tandem duplication of the FMS-like tyrosine kinase (FLT3-ITD) receptor is present in 20% of acute myeloid leukemia (AML) patients and it has been associated with an aggressive AML phenotype. "
07/15/2014 - "Internal tandem duplication of FMS-like tyrosine kinase (FLT3-ITD) is well known to be involved in acute myeloid leukemia (AML) progression, but FLT3-ITD-negative AML cases account for 70% to 80% of AML, and the mechanisms underlying their pathology remain unclear. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|7.||Interleukin-6 (Interleukin 6)
|8.||Brain Natriuretic Peptide (Natrecor)
|10.||pro-brain natriuretic peptide (1-76)
|1.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)
|5.||Prostatectomy (Retropubic Prostatectomy)